Herein, we would like to focus on new opportunities in the treatment of blood cancers, that can be provided by the specific inositol-requiring enzyme 1α (IRE1α) inhibitors. The gene discussed is ERN1; the disease is hematopoietic and lymphoid system neoplasm.